Market Place
Sourcing Support
Alkermes Presents Analyses From Long-Term Safety Study of LYBALV at SIRS
08 Apr 2024 //
PR NEWSWIRE
Alkermes Announces Topline Results From Study of LYBALVI
03 Jan 2024 //
PR NEWSWIRE
Alkermes` Lybalvi a new litmus test for mental illness marketing
24 Feb 2022 //
FIERCEPHARMA
Alkermes Shows Positive Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI
08 Feb 2022 //
PRNEWSWIRE
Alkermes schizophrenia drug gets U.S. FDA approval
02 Jun 2021 //
REUTERS
FDA Accepts Alkermes` Resubmission of New Drug Application for ALKS 3831
29 Dec 2020 //
PRNEWSWIRE
Journal of Clinical Psychiatry Publishes Data from Alkermes` Pha3 ALKS 3831
04 Mar 2020 //
PR NEWSWIRE
Did a disaster crush your stock in 2018? These biotechs were happy with CEO
03 May 2019 //
ENDPTS
FDA advisors turn down Alkermes’ ALKS 5461
03 Nov 2018 //
PHARMA TIMES
Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for MDD
30 Oct 2018 //
PR NEWSWIRE
Alkermes Announces Phase 3 Data for ALKS 5461 for Major Depressive Disorder
29 Oct 2018 //
PR NEWSWIRE
Alkermes to Present Data on Depression and Schizophrenia Portfolios
23 May 2018 //
PRESS RELEASE
Alkermes Receives Refusal to File Letter From FDA for ALKS 5461
02 Apr 2018 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.